Tianjin Pharmaceuticals Da Ren Tang's (SGX:T14) expects first-half net profit attributable to shareholders to slump 66% to 68% year on year to between 620 million yuan and 660 million yuan.
The company attributed the sharp drop to the absence of a 1.31 billion yuan after-tax one-off gain recorded in the first half of 2025 from the disposal of its remaining 12% stake in Tianjin TSKF Pharmaceutical.
Excluding non-recurring items, the company expects first-half net profit to increase 2% to 9% to between 610 million yuan and 650 million yuan,it said.